secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2024-08-06T23:59:59+00:00
Accession:  0000950170-24-091799
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Q2 net loss $30.4M; cash $239.1M; palazestrant combo shows 85% CBR
------------------------------------------------------------------------

- Net loss for Q2 2024 was $30.4M vs $20.1M in Q2 2023, driven by increased R&D spending on late-stage trials.
- Cash, cash equivalents and marketable securities of $239.1M as of June 30, 2024.
- Interim Phase 1b/2 data for palazestrant + ribociclib showed 85% clinical benefit rate in 13 evaluable patients.
- IND for KAT6 inhibitor OP-3136 expected to be filed with FDA in late 2024; pre-clinical data in Q4.
- Plan to initiate Phase 1b/2 study of palazestrant + everolimus in Q3 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024091799/0000950170-24-091799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000095017024091799/olma-20240806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-091799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer